FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Syndicate content

RNAi related Press Releases

Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer

Posted February 10, 2012

LONDON, February 10, 2012 /PRNewswire/ -- -- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer -- -- Thomas Christély resigns as a Director of the Company -- Silence Read more...

New RNA-based therapeutic strategies for controlling gene expression

Posted February 3, 2012

New RNA-based therapeutic strategies for controlling gene expression New Rochelle, NY, February 2, 2012-Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for Read more...

Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial Results

Posted February 2, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and Read more...

Alnylam Files Patent Infringement Suit Against Tekmira

Posted January 17, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a patent infringement lawsuit against Tekmira Read more...

Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics

Posted January 9, 2012

Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics LONDON, January 9, 2012 /PRNewswire/ -- - Third collaboration to Read more...

Alnylam and Arrowhead Form Collaboration and Licensing Agreement

Posted January 5, 2012

Alnylam and Arrowhead Form Collaboration and Licensing Agreement - Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) - - Alnylam Gains Access to Read more...

Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer

Posted January 4, 2012

WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Read more...

Access Pharmaceuticals Provides Third Quarter Update on MuGard Commercial Activities

Posted November 15, 2011

Company Schedules Investor Conference Call For Wednesday, December 7th at 11:00AM ESTDALLAS and NEW YORK, Nov. 15, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical Read more...

Alnylam to Webcast Conference Call Discussing Third Quarter 2011 Financial Results

Posted October 25, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter Read more...

Alnylam to Webcast Presentation at the Newsmakers in the Biotech Industry 2011 Conference

Posted October 20, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Read more...
123456next ›last »